Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy

Petru, Edgar; Andel, Johannes; Angleitner-Boubenizek, Lukas; Steger, G.; Bernhart, Marianne; Busch, Kerstin; Gehmacher, O.; Hernler, Tamara; U, Kastner; Lanz-Veit, A; Pluschnigg, Ursula; Polachova, Jana; Rohde, Michael; Schiller, Lothar; Schramböck, R; Stangl, Wolfgang; Thödtmann, R.; Zabernigg, August

doi:10.1007/s10354-008-0515-1

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Tang et al [19] reported that 30 µg/kg of palonosetron is the effective dose in reducing postoperative vomiting. In addition, a post-marketing surveillance reported tolerable adverse events at a higher dose of palonosetron in prophylaxis for CINV [20]. Therefore, we think that studies are necessary to determine the efficacy and safety of higher doses of palonosetron in the prevention of PONV.…”

Section: Discussionmentioning

confidence: 99%

A randomized, double-blind study to evaluate the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery

Park

Cho

Kang

et al. 2013

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundPostoperative nausea and vomiting (PONV) is a common complication after anesthesia and surgery; 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have been considered as a first-line therapy. Ramosetron and palonosetron are more recently developed drugs and have greater receptor affinity and a longer elimination half-life compared with older 5-HT3 receptor antagonists. The purpose of this study was to determine which drug is more effective for preventing PONV between ramosetron and palonosetron.MethodsWe enrolled 100 patients undergoing gynecological laparoscopic surgery into this study. The subjects were divided into ramosetron group and palonosetron group. The medications were provided immediately before the induction of anesthesia. The occurrence of nausea and vomiting, severity of nausea according to a visual analogue scale, and rescue anti-emetic drug use were monitored immediately after the end of surgery and at 0-6 h, 6-24 h, and 24-48 h post-surgery.ResultsThe incidence of vomiting was significantly lower in the palonosetron group than in the ramosetron group during 0-6 h (6% vs 26%, P = 0.012) and 0-48 h (14% vs 34%, P = 0.034). The incidence of nausea and overall PONV, and the use of rescue antiemetic were not significantly different during all time intervals. The severity of nausea was not different between the two groups.ConclusionsIn conclusion, the incidence of PONV between the ramosetron and the palonosetron group have not shown the difference during 0-48 h, although palonosetron results in a lower incidence of vomiting during 0-6 h post-surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized, double-blind study to evaluate the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery

Park

Cho

Kang

et al. 2013

Korean J Anesthesiol

View full text Add to dashboard Cite

show abstract

“…However, palonosetron is known to be safe at even higher doses [14,15]. Furthermore, Y-site administration of palonosetron has been reported to be compatible and stable with fentanyl [16].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting

Kang

Park

2014

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundThe efficacy of palonosetron in preventing postoperative nausea and vomiting (PONV), as well as chemotherapy-induced nausea and vomiting, has already been demonstrated in multiple clinical studies. The purpose of this study was to determine whether continuous infusion of palonosetron following single injection could reduce PONV to a greater extent than single injection only of palonosetron.MethodsIn total, 132 women were enrolled in the study. All subjects were over the age of 20 years and were scheduled to undergo gynecologic laparoscopic surgery. Patients were randomly allocated into two groups. In both groups, patients received 0.075 mg of palonosetron intravenously, immediately before induction of anesthesia. In the continuous palonosetron infusion group, 0.075 mg (1.5 ml) of palonosetron was added to the patient-controlled analgesia device. In the single-injection palonosetron group, 1.5 ml of normal saline was added.ResultsThe incidence of PONV 24 hours postoperatively was significantly lower in the continuous palonosetron infusion group than the single-injection palonosetron group (31.8 vs. 56.1%, P = 0.009).ConclusionsContinuous palonosetron infusion, following single injection, reduces the incidence of PONV compared with single injection only.

show abstract

“…Since palonosetron was approved by FDA, several more phase II and phase III trials have been published which may help clarify the above issues. 44,58–64 These are summarized in Table 2.…”

Section: Chemistry Mechanism Of Action and Pharmacokinetic Profilementioning

confidence: 99%

Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Roddy

Berger

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) is among the most unpleasant and stressful aspects of chemotherapy. Poorly controlled nausea and vomiting may have negative impacts on clinical treatment and quality of life. Clinical trials aimed at the prevention of CINV have focused on both acute and delayed phases of CINV. The use of first generation serotonin subtype 3 serotonin (5-HT3) receptor antagonists has significantly improved symptom control in acute CINV. However, they are less effective in controlling delayed CINV Palonosetron is a second generation 5-HT3 receptor antagonist with high potency, selectivity, prolonged half-life, and a unique allosteric binding mechanism. Previous trials which compared palonosetron to other first generation 5-HT3 antagonists had used the prevention of delayed CINV as a secondary end point. Recent data have demonstrated palonosetron, when used with a corticosteroid, was superior to granisetron in the prevention of delayed CINV as a primary end point. This article will review recently published literature focusing on mechanism of action, metabolism, pharmacokinetics, clinical efficacy, and safety of palonosetron in the treatment of CINV, specifically delayed CINV.

show abstract

Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy

Abstract: Palonosetron resulted in high antiemetic efficacy in this study. Female gender and age < or = 50 years should be particularly considered when the antiemetic regimen is selected.

Cited by 6 publications

References 8 publications

A randomized, double-blind study to evaluate the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery

A randomized, double-blind study to evaluate the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery

Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting

Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Contact Info

Product

Resources

About